Arvinas (ARVN) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kamada (KMDA) has outperformed Arvinas (ARVN) over the past year, gaining 18.6% versus a loss of 19.9%. Over five years, KMDA leads with a +49.7% price change compared with -91.2% for ARVN. Arvinas is the larger company by market cap ($468.7 million vs $444.4 million), about 1.1 times the size.
On valuation, Kamada trades at a lower trailing P/E (20.3x vs 27.9x for Arvinas). Kamada pays a dividend yielding 3.25%, while Arvinas does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | KMDA |
|---|---|---|
| Share price | $7.27 | $7.70 |
| Market cap | $468.75M | $444.37M |
| 1-day change | -2.48% | -2.41% |
| YTD return | -37.18% | +11.76% |
| 1-year return | -19.89% | +18.65% |
| 5-year return | -91.25% | +49.72% |
| P/E ratio (TTM) | 27.94 | 20.26 |
| Forward P/E | — | 13.35 |
| EPS (TTM) | $0.26 | $0.38 |
| Dividend yield | 0.00% | 3.25% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $14.51 | $9.35 |
| 52-week low | $6.97 | $6.55 |
| Distance from 52-week high | -49.93% | -17.65% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +91.74% | +75.32% |
| Average volume | 779.46K | 118.04K |
| Shares outstanding | 64.52M | 57.71M |
| Employees | 246 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed ARVN by 38.5 percentage points over the past year.
- Arvinas trades at a higher earnings multiple (27.9x vs 20.3x trailing P/E).
- Kamada offers a meaningfully higher dividend yield (3.25% vs 0.00%).
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
ARVN vs KMDA FAQ
Which is bigger, Arvinas or Kamada?
Arvinas (ARVN) is larger, with a market capitalization of $468.75M compared with $444.37M for Kamada (KMDA).
Which stock has performed better over the past year, ARVN or KMDA?
KMDA returned +18.65% over the past 12 months, compared with -19.89% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARVN or KMDA?
KMDA has the lower trailing P/E at 20.3, versus 27.9 for ARVN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Arvinas or Kamada?
Kamada pays a dividend yielding 3.25%, while Arvinas does not currently pay a regular dividend.
Are Arvinas and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.